• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Healthcare·DEVA.IS
Share

Deva Holding A.S. Stocks

TRY 90.5Last Updated 27.08.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

TRY 350.15M

TRY 90.5
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA, undervalued on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't fall quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

28.08.2026 18:31

Nvidia Has Put Some AI Cloud Deals on Hold Under a New Funding Program — WSJ

28.08.2026 17:55

Claude Has Entered the Real World: Anthropic Has Released an AI That Controls Lasers and Robotic Arms

28.08.2026 17:18

'A hot potato': Michael Burry is growing bearish on Build-A-Bear after 2Q earnings

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026